AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUL 22 min read$NKTR

Zalevsky Jonathan sold $398K of NKTR

Zalevsky Jonathan (Chief R&D Officer) sold 5,681 shares of NEKTAR THERAPEUTICS (NKTR) at $70.00 ($0.40M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Zalevsky Jonathan
Published Jul 2, 2026, 11:06 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 2, 2026, 11:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$NKTR
Neutral
high confidence
Mentioned
$NKTR
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$NKTRNeutralLow
01

Why it matters

The newest fact is the officer’s open-market sale details (shares, price, total value) executed under a pre-arranged 10b5-1 plan; no other company-specific news is provided.

02

Market read

Traders may note insider selling, but 10b5-1 structure and lack of new fundamentals make it low-impact.

03

What to watch

The filing doesn’t state net proceeds use, tax context, or whether other insiders/large holders acted—so the signal is inherently limited.

Relevance 3/10Novelty 5/10Timing: filed after-hours on 2026-07-02; reflects sale executed 2026-06-30

Background

The article is an SEC Form 4 insider transaction disclosure for NeKTAR Therapeutics (NKTR).

Company-level read

Ticker impact

$NKTRNeutralHigh confidence
Context

SEC Form 4 shows Chief R&D Officer Jonathan Zalevsky sold 5,681 NKTR shares at $70 on 2026-06-30 under a 10b5-1 plan.

Expected impact

Minimal near-term impact; any effect is likely short-lived and outweighed by normal trading/positioning.

Evidence & confidence

The filing is a pre-arranged 10b5-1 open-market sale by an officer, with no accompanying new operational, regulatory, or financial catalyst in the text.

Market effects

Sector

No sector read-through; this is company-specific insider transaction reporting.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it’s a 10b5-1 plan, the sale may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    NEKTAR THERAPEUTICS

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Zalevsky Jonathan

    Chief R&D Officer who sold shares under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

NKTR insider trading history →

Related articles

OCT 8
$LLYLow

Nektar v. Lilly: Lilly Defeats CRE Claim, But Jury Finds It Owes $90M For Breaching The Implied Covenant Of Good Faith And Fair Dealing

A federal jury ruled that Eli Lilly & Co. breached the implied covenant of good faith and fair dealing with Nektar Therapeutics, awarding Nektar $90 million in damages. The jury rejected Nektar's claim that Lilly breached the license agreement's commercially reasonable efforts (CRE) obligation. Lilly plans to appeal, arguing no liability should have been imposed. The case highlights risks in biopharma licensing agreements.

mondaq.com2 min
OCT 7
$NKTRLow

Nektar Therapeutics (NKTR): $115 Million Lawsuit Victory Over Eli Lilly Clears Multi-Year Overhang

Nektar Therapeutics (NKTR) won a $115 million lawsuit against Eli Lilly (LLY), resolving a multi-year overhang. The verdict, including interest, amounts to ~5% of NKTR's market cap. Despite the win, NKTR's stock fell over $200 million in market cap due to market volatility and rising yields. Cedar Grove Capital Management views this as a net positive for NKTR, removing a long-standing uncertainty.

finance.yahoo.com2 min
OCT 1
$NKTRMedAI 8/10

NKTR Stock Eyes Worst Day In Over 3 Years On Rezpeg Data: William Blair Still Sees A Durability Edge

Nektar Therapeutics (NKTR) shares fell 21% after reporting modest new response rates for its experimental skin drug, rezpegaldesleukin, in alopecia and eczema studies. Despite this, analysts at William Blair and Jefferies maintained bullish ratings, citing the drug's durability advantage. The company also faces an ongoing legal dispute with Eli Lilly.

newsable.asianetnews.com2 min